A Phase 3 Clinical Program Consisting of Two Multicenter, Double-Masked, Randomized, Sham-Controlled Trials COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in Combinatio
Research Grant
Awarded By
Opthea Limited
Start Date
December 4, 2024
End Date
September 4, 2025
Awarded By
Opthea Limited
Start Date
December 4, 2024
End Date
September 4, 2025